Clinical Laserthermia Systems AB Class B (CLS.B) AI Stock Analysis

• Market Cap: kr237.80M
• Dividend Yield: N/A
• Average Volume (3M): 333.29K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.29
• Revenue Growth: 14.18%
• EPS Growth: 72.73%
• Country: SE
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.32
• Shares Outstanding: 31,163,593
• 10 Day Avg. Volume: 370,302
• 30 Day Avg. Volume: 333,294
• PEG Ratio: 0.01
• Price to Book (P/B): 0.59
• Price to Sales (P/S): 2.15
• P/FCF Ratio: -0.68
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): kr37.10M

• Rating: 55 Neutral
• Price Target: kr8.00 ▲(17.82% Upside)

The score is held back primarily by weak financial performance—declining revenue, large ongoing losses, and continued cash burn—partly offset by a low-debt balance sheet. Technicals are a supportive factor with an uptrend and positive momentum, while valuation remains constrained by negative earnings and no stated dividend yield.

Positive Factors

High gross margins

A sustained gross margin near 67% indicates strong product-level economics typical for differentiated medical devices and consumables. This margin buffer supports long-term profitability as sales scale, enabling reinvestment in clinical studies, service infrastructure and product R&D without immediate margin pressure.

Very low leverage

Minimal debt materially reduces financial risk and preserves flexibility to fund commercialization or trials via equity or partnership rather than interest-bearing obligations. Over a 2–6 month horizon this conservatism supports survivability during scaling and cushions against revenue volatility.

Recurring revenue model elements

A business mix that includes consumables, service contracts and training creates recurring revenue potential tied to installed systems. As the installed base grows, these higher-margin, repeatable streams can stabilize cash flows and raise customer lifetime value, aiding durable commercialization.

Negative Factors

Declining, small revenue base

A shrinking and still small revenue base limits scale benefits and makes fixed costs burdensome, delaying operating leverage. Persisting revenue declines over several quarters hinder the firm's ability to fund trials, expand sales channels, and achieve self-sustaining growth without external financing.

Negative operating and free cash flow

Sustained negative operating and free cash flow forces reliance on external capital and increases dilution risk. Even with some improvement versus prior years, continued cash burn constrains investment in sales, clinical validation and regulatory work, slowing market penetration and long-term viability.

Eroding equity and heavy losses

Operating losses that materially erode equity reflect weak profitability and weaken the firm's financial resilience. Persistent steep net margins and declining equity limit capacity to invest organically, increase the likelihood of dilutive raises or restructuring, and impair long-term stakeholder confidence.

Clinical Laserthermia Systems AB Class B Business Overview & Revenue Model

Company Description

Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.

How the Company Makes Money

CLS.B generates revenue through the sale of its laser therapy systems and related consumables to hospitals, clinics, and healthcare providers. The company also earns income through service agreements for maintenance and support of its equipment, as well as training programs for healthcare professionals to ensure effective use of their technologies. Additionally, CLS.B may engage in strategic partnerships with medical institutions and research organizations to conduct clinical trials and studies that validate the effectiveness of their products, potentially leading to increased sales and market penetration. These partnerships can also provide access to funding and resources, contributing to the company's overall financial performance.

Clinical Laserthermia Systems AB Class B Financial Statement Overview

Summary

Despite improved gross margin (~67%) and narrowing losses versus prior years, revenue declined (~11% TTM) and profitability remains very weak (deeply negative margins). Cash flow is also a key concern with continued negative operating and free cash flow, while the balance sheet is a relative strength due to minimal leverage.

Income Statement

TTM (Trailing-Twelve-Months) revenue is still relatively small and declined about 11% versus the prior period, but gross margin remains strong at ~67% (improving from ~55% in 2024). The core issue is profitability: operating and net margins are deeply negative (net margin around -180% in TTM), indicating the cost base is far ahead of current scale. Losses have narrowed meaningfully from 2023–2024 levels, but the business is not yet demonstrating consistent operating leverage.

Balance Sheet

Leverage is very low, with debt-to-equity close to zero in both TTM and 2024, which reduces financial risk and provides flexibility. However, equity has declined from 2024 to TTM, and returns on equity remain sharply negative, reflecting ongoing losses eroding the capital base over time. Overall, the balance sheet looks conservatively financed, but continued losses are the key medium-term pressure point.

Cash Flow

Cash generation remains weak, with negative operating cash flow and negative free cash flow in both TTM and 2024, and TTM free cash flow deteriorating versus the prior year. Cash burn is broadly tracking accounting losses (free cash flow modestly larger in magnitude than net loss), suggesting limited near-term self-funding capacity. The main strength is that cash burn has improved versus 2023–2024 levels, but it is still substantial relative to the company’s revenue base.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	21.27M	18.78M	8.27M	6.27M	2.25M	1.33M
Gross Profit	14.28M	10.42M	3.00M	-2.79M	-3.63M	876.00K
EBITDA	-35.65M	-44.76M	-68.41M	-57.84M	-57.05M	-51.61M
Net Income	-38.38M	-47.62M	-79.79M	-70.66M	-63.62M	-57.94M
Balance Sheet
Total Assets	64.13M	78.56M	57.73M	49.51M	66.74M	44.40M
Cash, Cash Equivalents and Short-Term Investments	13.20M	22.51M	15.33M	10.59M	31.17M	11.87M
Total Debt	224.00K	224.00K	454.00K	30.68M	273.50K	673.50K
Total Liabilities	7.31M	12.88M	14.20M	41.64M	45.55M	30.47M
Stockholders Equity	59.56M	68.72M	45.77M	9.22M	21.79M	13.93M
Cash Flow
Free Cash Flow	-39.61M	-58.92M	-71.95M	-71.25M	-66.73M	-55.76M
Operating Cash Flow	-33.42M	-56.45M	-66.45M	-70.69M	-66.17M	-55.41M
Investing Cash Flow	-4.32M	-7.47M	-5.50M	-886.00K	-408.00K	-508.00K
Financing Cash Flow	35.35M	71.10M	76.69M	61.84M	85.88M	62.02M

Clinical Laserthermia Systems AB Class B Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.79
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:CLS.B, the sentiment is Positive. The current price of 6.79 is below the 20-day moving average (MA) of 7.71, below the 50-day MA of 7.30, and above the 200-day MA of 6.14, indicating a neutral trend. The MACD of 0.08 indicates Positive momentum. The RSI at 51.29 is Neutral, neither overbought nor oversold. The STOCH value of 50.91 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:CLS.B.

Clinical Laserthermia Systems AB Class B Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARCOMA	58 Neutral	kr103.88M	22.65	―	―	―	―
CLS.B	55 Neutral	kr237.80M	-4.46	-63.39%	―	14.18%	72.73%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NOSA	48 Neutral	kr156.10M	-14.53	―	―	17.24%	35.77%
LXB	44 Neutral	kr64.68M	-3.02	-60.20%	―	163.12%	30.50%
HEART	43 Neutral	kr140.96M	-0.85	―	―	―	―
SPEC	42 Neutral	kr71.50M	-0.48	-50.21%	―	―	-108.64%